Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial

Kapil Sharma, Sanjay Pant, Sriprakash Misra, Manisha Dwivedi, Alok Misra, Sushil Narang, Reshu Tewari, Ajeet S Bhadoria, Kapil Sharma, Sanjay Pant, Sriprakash Misra, Manisha Dwivedi, Alok Misra, Sushil Narang, Reshu Tewari, Ajeet S Bhadoria

Abstract

Background/aims: Minimal hepatic encephalopathy (MHE) implies subtle impairment of cognitive functions in the absence of features of overt encephalopathy. We aimed to determine the prevalence of MHE in patients with liver cirrhosis and to find out the effect of rifaximin, probiotics, and l-ornithine l-aspartate (LOLA) individually in reversal of MHE by comparing it with placebo group.

Patients and methods: This study was carried out in two phases. Phase I included the recruitment of 250 apparently healthy controls and extraction of normative data utilizing three neuropsychometric tests (NPTs) and critical flicker frequency (CFF) test. Phase II consisted of screening and recruitment of patients of MHE followed by drugs trial. A total of 317 cirrhotics were screened; 111 were excluded and the remaining 206 cirrhotics were screened for MHE using NPTs and/or CFF test. Of these, 124 patients with MHE were randomized to receive LOLA (n = 31), rifaximin (n = 31), probiotics (n = 32), for 2 months and were compared with patients who were given placebo (n = 30).

Results: Out of 206 cirrhotics, 124 (60.19%) had MHE. Among these 124 MHE patients, 87 (70.16%) patients had CFF <39Hz, 112 (90.32%) patients with MHE had two or more abnormal NPTs, and 75 (60.48%) patients had abnormality on both the CFF values and more than two abnormal NPTs. Intention-to-treat analysis showed the number of patients who improved after giving treatment were 67.7% (21/31), 70.9% (22/31), 50% (16/32), and 30% (9/30) for LOLA, rifaximin, probiotics, and placebo, respectively. CFF scores and improvement in psychometric tests after treatment were significantly higher (P < 0.05) for LOLA, rifaximin, and probiotics as compared with placebo group.

Conclusions: Prevalence of MHE is high in patients with cirrhosis of liver. Rifaximin, LOLA, and probiotics are better than giving placebo in patients with MHE.

Conflict of interest statement

Conflict of Interest: None declared.

References

    1. Groeneweg M, Quero JC, De Bruijn I, Hartmann IJ, Essink-bot ML, Hop WC, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998;28:45–9.
    1. Sharma P, Sharma BC, Puri V, Sarin SK. Minimal hepatic encephalopathy in patients with extra hepatic portal vein obstruction. Am J Gastroenterol. 2008;103:1406–12.
    1. Dhiman RK, Saraswat VA, Verma M, Naik SR. Figure Connection Test: A universal test for assessment of mental state. J Gastroenterol Hepatol. 1995;10:14–23.
    1. Kircheis G, Wettstein M, Timmermann L, Schnitzler A, Haussinger D. Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology. 2002;35:357–66.
    1. Weissenborn K, Ennen JC, Schomerus H, Ruckert N, Hecker H. Neurophysiological characterization of hepatic encephalopathy. J Hepatol. 2001;34:768–73.
    1. Saxena N, Bhatia M, Joshi YK, Garg PK, Dwivedi SN, Tandon RK. Electrophysiological and neuropsychological tests for the diagnosis of subclinical hepatic encephalopathy and prediction of overt encephalopathy. Liver. 2002;22:190–7.
    1. De Bruijn KM, Blendis LM, Zilm DH, Carlen PL, Anderson GH. Effect of dietary protein manipulation in subclinical portal-systemic encephalopathy. Gut. 1983;24:53–60.
    1. Kircheis G, Nilis R, Held C, Berndt H, Buchner M, Görtelmeyer R, et al. Therapeutic efficacy of l-ornithine-l-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: Results of placebo-controlled, double-blind study. Hepatology. 1997;25:1351–60.
    1. Watanabe A, Sakai T, Sato S, Imai F, Ohto M, Arakawa Y, et al. Clinical efficacy of lactlulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology. 1997;26:1410–4.
    1. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology. 2004;39:1441–9.
    1. Ortiz M, Cordoba J, Doval E, Jacas C, Pujadas F, Esteban R, et al. Development of a clinical hepatic encephalopathy staging scale. Aliment Pharmacol Ther. 2007;26:857–67.
    1. Munoz SJ. Hepatic Encephalopathy. Med Clin North Am. 2008;92:795–812.
    1. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, Garcia E, Agilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001;96:2718–23.
    1. Sharma P, Sharma BC, Puri V, Sarin SK. Critical flicker frequency: Diagnostic tool for minimal hepatic encephalopathy. J Hepatol. 2007;47:67–73.
    1. Dhiman RK, Saraswat VA, Sharma BK, Sarin SK, Chawla YK, Butterworth R, et al. Indian National Association for Study of the Liver. Minimal hepatic encephalopathy: Consensus statement of a working party of the Indian National Association for Study of the Liver. J Gastroenterol Hepatol. 2010;25:1029–41.
    1. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology. 2007;45:549–59.
    1. Ortiz M, Jacas C, Cordoba J. Minimal hepatic encephalopathy: Diagnosis, clinical significance and recommendations. J Hepatol. 2005;42(Suppl 1):S45–53.
    1. Lockwood AH, Yap EW, Wong WH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cerb Blood Flow Metab. 1991;11:337–41.
    1. Cordoba J, Alonso J, Rovira A, Jacas C, Sanpedro F, Castells L, et al. The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1) H-magnetic resonance abnormalities after liver transplantation. J Hepatol. 2001;35:598–604.
    1. Mittal VV, Sharma P, Sharma BC, Sarin S. Treatment of minimal hepatic encephalopathy: A randomised controlled trial comparing lactulose, probiotics and l-ornithine l-aspartate with placebo. Hepatology. 2009;50(Suppl):471A.
    1. Davies NA, Wright G, Ytrebø LM, Stadlbauer V, Fuskevåg OM, Zwingmann C, et al. l-Ornithine and phenylacetate synergestically produce sustained reduction in ammonia and brain water in cirrhotic rats. Hepatology. 2009;50:155–64.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться